Thoratec On Track For Late 2015 HeartMate III Launch
This article was originally published in The Gray Sheet
Enrollment has been completed in the firm's 50-patient trial to support a European CE mark of its next generation HeartMate III.
You may also be interested in...
The long-time leader of the ventricular assist device market Thoratec is implementing plans to get back on track for future growth, while rival HeartWare recently reported rapid global expansion and aggressive R&D investments.
Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.
The European Safety Authority is running consultations on its proposals to set safe intake levels from foods, including dietary supplements, for iron and vitamin A.